These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1905629)
1. Decreased insulin secretory capacity and normal pancreatic B-cell glucose sensitivity in non-obese patients with NIDDM. Van Haeften TW; Van Maarschalkerweerd WW; Gerich JE; Van der Veen EA Eur J Clin Invest; 1991 Apr; 21(2):168-74. PubMed ID: 1905629 [TBL] [Abstract][Full Text] [Related]
2. Dose-response characteristics for glucose-stimulated insulin release in man and assessment of influence of glucose on arginine-stimulated insulin release. van Haeften TW; Boonstra E; Veneman TF; Gerich JE; van der Veen EA Metabolism; 1990 Dec; 39(12):1292-9. PubMed ID: 2246970 [TBL] [Abstract][Full Text] [Related]
3. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients. Kruszynska YT; Goulas S; Wollen N; McIntyre N J Hepatol; 1998 Feb; 28(2):280-91. PubMed ID: 9514541 [TBL] [Abstract][Full Text] [Related]
4. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. Ward WK; Bolgiano DC; McKnight B; Halter JB; Porte D J Clin Invest; 1984 Oct; 74(4):1318-28. PubMed ID: 6384269 [TBL] [Abstract][Full Text] [Related]
5. Quantitative and qualitative differences in basal and glucose- and arginine-stimulated insulin secretion in healthy subjects and different stages of NIDDM. Ratheiser K; Reitgruber W; Komjati M; Bratusch-Marrain P; Vierhapper H; Waldhäusl WK Acta Diabetol Lat; 1990; 27(3):197-213. PubMed ID: 2075783 [TBL] [Abstract][Full Text] [Related]
6. Dose-response characteristics for arginine-stimulated insulin secretion in man and influence of hyperglycemia. van Haeften TW; Voetberg GA; Gerich JE; van der Veen EA J Clin Endocrinol Metab; 1989 Nov; 69(5):1059-64. PubMed ID: 2677037 [TBL] [Abstract][Full Text] [Related]
7. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility. Fritsche A; Stefan N; Hardt E; Schützenauer S; Häring H; Stumvoll M Eur J Clin Invest; 2000 May; 30(5):411-8. PubMed ID: 10809901 [TBL] [Abstract][Full Text] [Related]
8. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. Gumbiner B; Polonsky KS; Beltz WF; Griver K; Wallace P; Brechtel G; Henry RR J Clin Endocrinol Metab; 1990 Jun; 70(6):1594-602. PubMed ID: 2189885 [TBL] [Abstract][Full Text] [Related]
9. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556 [TBL] [Abstract][Full Text] [Related]
10. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects. Levy JC; Rudenski A; Burnett M; Knight R; Matthews DR; Turner RC Diabetologia; 1991 Jul; 34(7):488-99. PubMed ID: 1916054 [TBL] [Abstract][Full Text] [Related]
11. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Clark HE; Matthews DR Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981 [TBL] [Abstract][Full Text] [Related]
12. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Chen KW; Boyko EJ; Bergstrom RW; Leonetti DL; Newell-Morris L; Wahl PW; Fujimoto WY Diabetes Care; 1995 Jun; 18(6):747-53. PubMed ID: 7555498 [TBL] [Abstract][Full Text] [Related]
13. Effect of increased plasma non-esterified fatty acids (NEFAs) on arginine-stimulated insulin secretion in obese humans. Carpentier A; Giacca A; Lewis GF Diabetologia; 2001 Nov; 44(11):1989-97. PubMed ID: 11719829 [TBL] [Abstract][Full Text] [Related]
14. Effect of epinephrine on pancreatic beta-cell and alpha-cell function in patients with NIDDM. Ortiz-Alonso FJ; Herman WH; Zobel DL; Perry TJ; Smith MJ; Halter JB Diabetes; 1991 Sep; 40(9):1194-202. PubMed ID: 1936624 [TBL] [Abstract][Full Text] [Related]
16. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393 [TBL] [Abstract][Full Text] [Related]
17. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533 [TBL] [Abstract][Full Text] [Related]
18. Effect of acute administration of gliclazide on the glucose sensitivity of pancreatic B-cells in healthy subjects. Veneman TF; van Haeften TW; van der Veen EA Clin Sci (Lond); 1991 Jul; 81(1):101-6. PubMed ID: 1649715 [TBL] [Abstract][Full Text] [Related]
19. Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus. Fernández-Castañer M; Biarnés J; Camps I; Ripollés J; Gómez N; Soler J Diabet Med; 1996 Nov; 13(11):953-9. PubMed ID: 8946153 [TBL] [Abstract][Full Text] [Related]
20. A comparison of four methods for assessing in vivo beta-cell function in normal, obese and non-insulin-dependent diabetic man. Davis SN; Piatti PM; Monti L; Möller N; Ng LL; Coppack S; Antsiferov M; Brown MD; Alberti KG Diabetes Res; 1992 Mar; 19(3):107-17. PubMed ID: 1286545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]